Full-Time
Clinical Sales Specialist
CS
Posted on 7/30/2025
Corcept Therapeutics
501-1,000 employees
develops cortisol-modulating therapies for Cushing's syndrome
Compensation Overview
$140k - $155k/yr
Pittsburgh, PA, USA
In Person
 Sales & Account Management (3) |
|---|
| , , |
- BA/BS or equivalent work experience
- 5+ years sales experience required, recent endocrine relationships, specialty therapeutic, hospital, or orphan drugs sales experience highly preferred
- Applicants must be currently authorized to work in the United States on a full-time basis
- Build and develop professional relationships with influential high prescribers and thought leaders in the territory to enhance Corcept brand and product loyalty
- Leverages expertise and knowledge of the therapeutic disease state, the marketplace, applicable competitors, industry, and cross-functional activities/plans to anticipate and effectively manage business opportunities and challenges
- Develops and implements effective customer specific territory plans and communicates insights to internal stakeholders
- Prioritizes time and effort to ensure optimal coverage of appropriate physician specialists based on opportunity and potential
- Plan and participate in education programs and speaker dinner programs
- Manage territory expenses/budget to support sales and marketing activities
- Proven track record of consistent high performance
- Strong ability to collaborate and work cross-functionally
- Required to travel up to 100% of the time, including up to 40% overnight travel
- Must maintain a driving record in accordance with Corcept vehicle policy
- Able to lift and/or move up to 35 pounds
Corcept Therapeutics develops and commercializes cortisol modulators to treat disorders caused by abnormal cortisol levels. Its main product, Korlym (mifepristone), blocks cortisol activity and is approved by the FDA for hypercortisolism in Cushing's syndrome; the company also works on additional cortisol-modulating treatments in its pipeline. The focus on specific cortisol modulation sets it apart, supported by ongoing R&D and education initiatives for healthcare professionals and patients. The company aims to improve outcomes for patients with Cushing's syndrome and other cortisol-related disorders by expanding access to effective therapies and advancing new treatments.
Company Size
501-1,000
Company Stage
IPO
Headquarters
Menlo Park, California
Founded
1998
Simplify's Take
What believers are saying
- Lifyorli gained NCCN preferred status with over 200 physicians prescribing since March 2026.
- 2026 revenue guidance raised to $950M–$1.05B after Q1 $164.9M sales beat expectations.
- Pipeline expands relacorilant to endometrial, cervical, pancreatic, prostate cancers via BELLA trials.
What critics are saying
- Teva launches generic Korlym after Federal Circuit invalidates patents, eroding 80% revenue.
- Relacorilant Cushing's NDA rejected December 30, 2025 by FDA Complete Response Letter.
- Securities class action over NDA misrepresentations settles by April 21, 2026 deadline.
What makes Corcept Therapeutics unique
- Corcept pioneered cortisol modulation with Korlym approved in 2012 for Cushing's syndrome.
- Lifyorli is first FDA-approved selective glucocorticoid receptor antagonist for ovarian cancer.
- ROSELLA trial showed 4.1-month OS benefit in platinum-resistant ovarian cancer patients.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Remote Work Options
Flexible Work Hours
Growth & Insights and Company News
6 month growth
↑ 4%1 year growth
↑ 6%2 year growth
↑ 5%Corcept Therapeutics is seeing divergent analyst views following legal and regulatory developments. H.C. Wainwright maintained its Buy rating but slashed its price target to $67 from $105, citing a court decision that removed the prospect of blocking Teva's generic Korlym. However, Wolfe Research upgraded the stock, viewing the risk-reward profile as more attractive at current valuations. The FDA approved Lifyorli (relacorilant) combined with nab-paclitaxel for platinum-resistant ovarian cancer, based on the ROSELLA trial showing a 35% reduction in death risk. Corcept also submitted a Marketing Authorisation Application to the European Medicines Agency for the same indication. The company issued 2026 revenue guidance of $900 million to $1 billion, whilst facing a securities class action lawsuit alleging it misled investors about FDA approval risks.
Corcept Therapeutics presented final data from its pivotal Phase 3 ROSELLA trial at the Society of Gynecologic Oncology 2026 Annual Meeting, with simultaneous publication in The Lancet. The trial evaluated Lifyorli (relacorilant) combined with nab-paclitaxel in patients with platinum-resistant ovarian cancer. The trial met its dual primary endpoints. Patients receiving Lifyorli plus nab-paclitaxel experienced a 35% reduction in death risk compared to nab-paclitaxel alone, with median overall survival of 16.0 months versus 11.9 months. Disease progression risk was reduced by 30%. Lifyorli, approved by the FDA in March 2026, is the first FDA-approved selective glucocorticoid receptor antagonist. The combination has been added to NCCN Clinical Practice Guidelines as a preferred regimen for platinum-resistant ovarian cancer. The trial enrolled 381 patients across multiple countries.
Deadline is April 21, 2026 to lead in securities class action against Corcept Therapeutics, Inc. (NASDAQ: CORT) - contact Kaplan Fox. Mar. 28, 2026 6:30 AM ET Source: Kaplan Fox NEW YORK, NY - March 28, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Corcept Therapeutics, Inc. ("Corcept" or the "Company") (NASDAQ: CORT) on behalf of all persons or entities that purchased or otherwise acquired Corcept common stock between October 31, 2024, and December 30, 2025, inclusive (the "Class Period"). If you are a Corcept investor and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing [email protected] or by calling (212) 329-8571. DEADLINE REMINDER: If you are a member of the proposed Class, you may move the court no later than April 21, 2026 to serve as a lead plaintiff for the purported class. If you have losses we encourage you to contact us to learn more about the lead plaintiff process. You need not seek to become a lead plaintiff in order to share in any possible recovery. According to the complaint, "Corcept is a pharmaceutical company focused on the development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. One of its lead new product candidates is relacorilant, which is being developed for multiple indications, including as a treatment for patients with hypercortisolism (also known as "Cushing's syndrome"). The complaint further alleges that "Defendants' Class Period representations that the relacorilant NDA was supported by powerful evidence, that it was approaching approval, and that they had no concerns about the FDA's review were false. In truth, the FDA had repeatedly raised concerns about the adequacy of the clinical evidence supporting the NDA and, as a result, there was a known material risk that Corcept's relacorilant NDA would not be approved." The complaint alleges that the "[t]he truth emerged on December 31, 2025, when Corcept revealed that the FDA had issued a Complete Response Letter... regarding the NDA for relacorilant as a treatment for patients with hypercortisolism. The press release issued by the Company stated that the FDA had 'concluded it could not arrive at a favorable benefit-risk assessment for relacorilant without Corcept providing additional evidence of effectiveness.' The press release quoted Defendant Belanoff as stating that '[w]e are surprised and disappointed by this outcome.' As a result of this disclosure, the price of Corcept common stock declined by $35.40 per share, or 50.4%." WHY CONTACT KAPLAN FOX - Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey. With over 50 years of experience in securities litigation, Kaplan Fox offers the professional experience and track record that clients demand. Through prosecuting cases on the federal and state levels, Kaplan Fox has successfully shaped the law through winning many important decisions on behalf of our clients. For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at www.kaplanfox.com. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Past results do not guarantee future outcomes. If you have any questions about this investigation, please contact: Laurence D. King KAPLAN FOX & KILSHEIMER LLP 1999 Harrison Street, Suite 1501 Oakland, California 94612 (415) 772-4704 [email protected] Contacting or submitting information to Kaplan Fox & Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.
Corcept Therapeutics shares gained nearly 9% this week after receiving US Food and Drug Administration approval for Lifyorli, its leading drug candidate. The treatment was approved for use in combination with nab-paclitaxel to treat platinum-resistant fallopian tube, primary peritoneal and ovarian cancer in patients who previously received one to three systemic treatment regimes. Following the announcement on Wednesday, Wolfe Research analyst Kalpit Patel upgraded his recommendation from underperform to peerperform, though he expressed concerns about the company's Korlym drug weighing on growth potential. The approval demonstrates Corcept's cortisol-focused development approach can succeed beyond Cushing's syndrome treatment, giving the biotech a marketable product in the high-demand cancer segment.
Onco360, the largest independent specialty pharmacy in the US, has been selected as the national pharmacy partner for LIFYORLI (relacorilant) by Corcept Therapeutics. LIFYORLI is indicated in combination with nab-paclitaxel for treating adults with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer who have received one to three prior systemic treatment regimens. LIFYORLI is a reversible glucocorticoid receptor antagonist. Its approval was based on the phase 3 ROSELLA study, which enrolled 381 patients and met its dual primary endpoints of progression-free and overall survival. Onco360, founded in 2003 and headquartered in Louisville, Kentucky, operates URAC- and ACHC-accredited oncology pharmacies nationwide, providing clinical support services for oncologists, patients and healthcare facilities.